- Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinomaby Asmerom T Sengal on 2022-07-22
Endometrial carcinoma (EC) is the most common gynecological malignancy and fibroblast growth factor receptor 2 (FGFR2) is a frequently dysregulated receptor tyrosine kinase. FGFR2b and FGFR2c are the two main splice isoforms of FGFR2 and are normally localized in epithelial and mesenchymal cells, respectively. Previously, we demonstrated that FGFR2c mRNA expression was associated with aggressive tumor characteristics, shorter progression-free survival (PFS), and disease-specific survival (DSS)...
- Molecular subclassification of vulvar squamous cell carcinoma: reproducibility and prognostic significance of a novel surgical techniqueby Emily F Thompson on 2022-06-28
CONCLUSION: Interobserver reproducibility of vulvar squamous cell carcinoma subclassification based on p16 and p53 immunohistochemistry may support routine use in clinical practice. Vulvar field resection surgery showed no significant difference in clinical outcomes when stratified based on HPV status.
- Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscapeby Amy Jamieson on 2022-06-03
Endometrial carcinoma (EC) classification and risk stratification have undergone a global transformation in the last decade, shifting from a reliance on poorly reproducible histomorphological parameters such as grade and histotype, toward a molecular classification that is consistent and biologically informative. Molecular classification enables reliable categorization of ECs, provides prognostic information, and is now beginning to drive clinical management, including surgery and adjuvant...
- Opportunistic salpingectomy between 2011 and 2016: a descriptive analysisby Gillian E Hanley on 2022-05-31
BACKGROUND: Opportunistic salpingectomy (OS) is the removal of fallopian tubes during hysterectomy for benign indications or instead of tubal ligation, for the purpose of preventing ovarian cancer. We determined rates of OS at the time of hysterectomy and tubal sterilization and examined how they changed over the study period.
- Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastasesby Amy Jamieson on 2022-05-03
CONCLUSION: EC molecular subtype is significantly associated with the presence of LNM. As molecular classification can be obtained on preoperative diagnostic specimens, this information can be used to guide surgical treatment planning and may reduce the cost and morbidity of unnecessary lymph node staging in EC care.
- BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitorsby Mattia Cremona on 2022-05-02
CONCLUSION: A clinical trial may be justified to further investigate the utility of IAP inhibitors.
- Differentiated Exophytic Vulvar Intraepithelial Lesions: Case Reports and Review of Literatureby Ariel R Mendlowitz on 2022-04-25
CONCLUSIONS: Differentiated vulvar intraepithelial lesions and invasive squamous cell carcinoma should be considered in the differential diagnosis of vulvar itch associated with hypertrophic plaques in postmenopausal women. Excision of suspicious plaques is recommended for definitive diagnosis.
- Endometrial cancerby Emma J Crosbie on 2022-04-10
Endometrial cancer is the most common gynaecological cancer in high income countries and its incidence is rising globally. Although an ageing population and fewer benign hysterectomies have contributed to this trend, the growing prevalence of obesity is the major underlying cause. Obesity poses challenges for diagnosis and treatment and more research is needed to offer primary prevention to high-risk women and to optimise endometrial cancer survivorship. Early presentation with postmenopausal...
- Variation in practice in endometrial cancer and potential for improved care and equity through molecular classificationby Amy Jamieson on 2022-03-05
CONCLUSION: Molecular classification has the potential to mitigate the profound variation in practice demonstrated in current EC care, enabling reproducible risk assessment, guiding treatment and reducing health care disparities.
- Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Preventionby Gillian E Hanley on 2022-02-09
CONCLUSIONS AND RELEVANCE: In this cohort study, the OS group had significantly fewer serous and epithelial ovarian cancers than were expected according to the rate at which they arose in the control group. These findings suggest that OS is associated with reduced ovarian cancer risk.
- From biobank and data silos into a data commons: convergence to support translational medicineby Rebecca Asiimwe on 2021-12-05
CONCLUSIONS: Proper infrastructures for data collection, sharing and governance is a translational research imperative. We have consolidated our data holdings into a data commons, along with standardized operating procedures to meet research and ethics requirements of the gynecologic cancer community in British Columbia. The developed infrastructure brings together, diverse data, computing frameworks, as well as tools and applications for managing, analyzing, and sharing data. Our data commons...
- The emerging role of molecular pathology in directing the systemic treatment of endometrial cancerby Amy Jamieson on 2021-08-19
Following the discovery of the four molecular subtypes of endometrial cancer (EC) by The Cancer Genome Atlas (TCGA) in 2013, subsequent studies used surrogate markers to develop and validate a clinically relevant EC classification tool to recapitulate TCGA subtypes. Molecular classification combines focused sequencing (POLE) and immunohistochemistry (mismatch repair and p53 proteins) to assign patients with EC to one of four molecular subtypes: POLEmut, MMRd, p53abn and NSMP (no specific...
- Reply to Survival analysis and treatment effects in patients with endometrial cancer and POLE mutationsby Aline Talhouk on 2021-07-27
- Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysisby Jessica N McAlpine on 2021-04-01
CONCLUSIONS: Clinical outcomes for ECs with pathogenic POLE mutations are not associated with most traditional risk parameters, and patients do not appear to benefit from adjuvant therapy. The observed low rates of recurrence/progression and the high and sustained salvage rates raise the possibility of safely de-escalating treatment for these patients.
- p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classificationby Amy Jamieson on 2021-02-16
Over the past decade, our understanding of endometrial cancer has changed dramatically from the two-tiered clinicopathologic classification system of type I and type II endometrial cancer through to the four distinct molecular subtypes identified by The Cancer Genome Atlas (TCGA) in 2013. In both systems there is a small subset of endometrial cancers (serous histotype/high numbers of somatic copy number abnormalities) that account for a disproportionately high percentage of endometrial cancer...